arrow
C

Cristina Papayannidis

IRCCS Azienda Ospedaliero-Universitaria di Bologna
H指数:43
被引数:6,982

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Omaveloxolone potentiates BET protein inhibition under hypoxia by disrupting metabolic and translational programs in acute myeloid leukemia cells

奥马波唑通过破坏急性髓系白血病细胞中的代谢和翻译程序,在缺氧条件下增强BET蛋白抑制

2026-08-210
OA
An Italian cartography of VEXAS‐related thrombosis

意大利学者对VEXAS相关血栓形成的制图研究

2026-08-170
OAAI
Real-Life Study on Gilteritinib-Related Infections (GilteRInf): An Italian SEIFEM Study

Gilteritinib相关感染的Real-Life研究(GilteRInf):一项意大利SEIFEM研究

2026-07-280
OAAI
LY09 Disease status at haematopoietic stem cell transplantation, including skin-limited disease, and survival in blastic plasmacytoid dendritic cell neoplasm: a retrospective, multicentre cohort study of the European Organisation for Research and Treatment of Cancer, Cutaneous Lymphoma Tumour Group

LY09 骨髓移植时的疾病状态,包括皮肤局限性病变,与暴发性浆样树突状细胞肿瘤的生存率:欧洲癌症研究与治疗组织皮肤淋巴瘤肿瘤组的回顾性、多中心队列研究

2026-06-260
OAAI
Characteristics and Outcomes of Progressive Multifocal Leukoencephalopathy in Hematologic Malignancies: A SEIFEM Retrospective Review

进展性多灶性白质脑症在血液系统恶性肿瘤中的特征与结局:一项SEIFEM回顾性研究

2026-03-270
OAAI
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort
2026-01-130
OAAI
Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia

更正:CPX-351在60岁以下继发急性髓系白血病患者中的真实世界多中心疗效分析

2025-12-040
OAAI
Outcome of Adult Lymphoblastic Lymphoma Patients Treated in the Real Life According to the Gimema LAL1913 Protocol: A Campus ALL Multicenter Study
2025-11-120
PRE
Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients

Gilteritinib在二线治疗后的有效性:一项关于171例复发/难治性FLT3突变急性髓系白血病患者的真实世界多中心研究

2025-11-010
OAAI
Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study

Venetoclax联合去甲基化药物作为异基因干细胞移植治疗复发/难治性急性髓系白血病的有效桥梁疗法:AVALON研究的一项亚组分析

2025-11-010
OAAI
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia

真实世界多中心分析CPX-351在60岁以下继发性急性髓系白血病患者中的疗效

2025-10-260
OA
Venetoclax plus hypomethylating agents as first salvage therapy for myeloid malignancies relapsing after allogeneic HSCT

维奈克拉 plus 低甲基化药物作为异基因HSCT后复发的髓系恶性肿瘤的首次挽救性治疗

2025-10-210
PRE
Impact of clinical response and treatment tolerability on HRQoL in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib

纳拉蒂布或伊马替尼治疗新诊断的费城染色体阳性急性淋巴细胞白血病患者中,临床反应和治疗耐受性对健康相关生活质量的影响

2025-10-100
OA
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation

真实世界研究:异基因干细胞移植的最佳CPX-351治疗时长与时机

2025-09-240
OAAI
Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group

培门冬酶(Pegaspargase)在55岁及以上急性淋巴细胞白血病患者的给药方案与耐受性研究:LAL1913方案的子分析,Campus ALL研究组。

2025-08-270
OAAI
Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience

Gilteritinib在FLT3突变急性髓系白血病中的治疗:一项意大利真实世界经验

Cancer
IF5.1
2025-08-210
OAAI
Real World Incidence and Etiology of Infectious Complications in Adults With Ph-Negative Acute Lymphoblastic Leukemia Treated With the Pediatric-Inspired GIMEMA LAL1913 Program. A Campus All Study

真实世界中接受儿科启发式GIMEMA LAL1913方案治疗的Ph阴性急性淋巴细胞白血病成人患者的感染并发症发生率和病因学。一项Campus All研究

2025-08-110
OA